Emerging opportunities in the viral vector manufacturing market include personalized medicine growth, expanded clinical trials, and regional manufacturing partnerships. Advances in bioprocessing and ...

Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site ...

France's Institut Pasteur will keep its three COVID-19 vaccine projects running despite recent reports of high efficacy rates in two experimental shots by Moderna and Pfizer -BioNTech , , its science ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s ...

Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of AAV production for gene therapies.

Therapeutics Co. Ltd. ( ($HK:2126) ) has issued an announcement. JW Therapeutics announced that the National Medical Products ...

Shattuck Labs, Inc. ( NASDAQ: STTK) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT ...

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

T-cell therapy has revolutionised the treatment of B-cell malignancies, offering durable responses for patients with relapsed or refractory disease. However, access globally remains limited due to ...